Literature DB >> 25975944

Serious and potentially life threatening complications of cardiac stress testing: Physiological mechanisms and management strategies.

Vasken Dilsizian1, Henry Gewirtz2, Nicholas Paivanas3, Anastasia N Kitsiou4, Fadi G Hage5, Nathan E Crone6, Ronald G Schwartz7.   

Abstract

Mesh：

Substances：

Year:  2015        PMID： 25975944     DOI： 10.1007/s12350-015-0141-4

Source DB:  PubMed          Journal:  J Nucl Cardiol        ISSN： 1071-3581            Impact factor:   5.952


× No keyword cloud information.
  115 in total

1.  Recommendations for clinical exercise laboratories: a scientific statement from the american heart association.

Authors:  Jonathan Myers; Ross Arena; Barry Franklin; Ileana Pina; William E Kraus; Kyle McInnis; Gary J Balady
Journal:  Circulation       Date:  2009-06-01       Impact factor: 29.690

2.  18F-FDG uptake as a surrogate marker for antecedent ischemia.

Authors:  Vasken Dilsizian
Journal:  J Nucl Med       Date:  2008-11-07       Impact factor: 10.057

3.  PACES/HRS expert consensus statement on the management of the asymptomatic young patient with a Wolff-Parkinson-White (WPW, ventricular preexcitation) electrocardiographic pattern: developed in partnership between the Pediatric and Congenital Electrophysiology Society (PACES) and the Heart Rhythm Society (HRS). Endorsed by the governing bodies of PACES, HRS, the American College of Cardiology Foundation (ACCF), the American Heart Association (AHA), the American Academy of Pediatrics (AAP), and the Canadian Heart Rhythm Society (CHRS).

Authors:  Mitchell I Cohen; John K Triedman; Bryan C Cannon; Andrew M Davis; Fabrizio Drago; Jan Janousek; George J Klein; Ian H Law; Fred J Morady; Thomas Paul; James C Perry; Shubhayan Sanatani; Ronn E Tanel
Journal:  Heart Rhythm       Date:  2012-05-10       Impact factor: 6.343

Review 4.  International Union of Basic and Clinical Pharmacology. LXXXI. Nomenclature and classification of adenosine receptors--an update.

Authors:  Bertil B Fredholm; Adriaan P IJzerman; Kenneth A Jacobson; Joel Linden; Christa E Müller
Journal:  Pharmacol Rev       Date:  2011-02-08       Impact factor: 25.468

5.  Absolute quantitation of coronary steal induced by intravenous dipyridamole.

Authors:  O O Akinboboye; O Idris; R L Chou; R R Sciacca; P J Cannon; S R Bergmann
Journal:  J Am Coll Cardiol       Date:  2001-01       Impact factor: 24.094

6.  Complete heart block associated with regadenoson: a real side effect.

Authors:  Anil Pandit; Samuel Unzek Freiman
Journal:  J Nucl Cardiol       Date:  2012-08-23       Impact factor: 5.952

7.  Physiological basis for angina and ST-segment change PET-verified thresholds of quantitative stress myocardial perfusion and coronary flow reserve.

Authors:  Nils P Johnson; K Lance Gould
Journal:  JACC Cardiovasc Imaging       Date:  2011-09

8.  Left ventricular performance in normal subjects: a comparison of the responses to exercise in the upright and supine positions.

Authors:  L R Poliner; G J Dehmer; S E Lewis; R W Parkey; C G Blomqvist; J T Willerson
Journal:  Circulation       Date:  1980-09       Impact factor: 29.690

9.  Regadenoson versus dipyridamole hyperemia for cardiac PET imaging.

Authors:  Nils P Johnson; K Lance Gould
Journal:  JACC Cardiovasc Imaging       Date:  2015-03-18

Review 10.  Regadenoson use in patients with chronic obstructive pulmonary disease: the state of current knowledge.

Authors:  Yasmeen Golzar; Rami Doukky
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2014-01-22
View more
  17 in total

1.  Cardiovascular risk assessment with regadenoson SPECT MPI in patients with end-stage renal disease is safe, effective, and well tolerated: Does it matter?

Authors:  Erica O Miller; Ronald G Schwartz
Journal:  J Nucl Cardiol       Date:  2015-12-01       Impact factor: 5.952

2.  Ventricular tachycardia during regadenoson SPECT myocardial perfusion imaging.

Authors:  Efstathia Andrikopoulou; Steven G Lloyd; Fadi G Hage
Journal:  J Nucl Cardiol       Date:  2015-12-01       Impact factor: 5.952

3.  Vasodilator stress agents for myocardial perfusion imaging.

Authors:  Rayan Saab; Fadi G Hage
Journal:  J Nucl Cardiol       Date:  2016-02-02       Impact factor: 5.952

4.  Safety of stress testing in patients with elevated cardiac biomarkers: Are all modalities created equal?

Authors:  Rami Doukky; Yasmeen Golzar
Journal:  J Nucl Cardiol       Date:  2016-02-17       Impact factor: 5.952

5.  Choosing exercise or pharmacologic stress imaging, or exercise ECG testing alone: How to decide.

Authors:  Jorge A Gonzalez; George A Beller
Journal:  J Nucl Cardiol       Date:  2016-02-03       Impact factor: 5.952

6.  Safety of vasodilator stress myocardial perfusion imaging in patients with elevated cardiac biomarkers.

Authors:  Mridula Rai; Alan W Ahlberg; Julianna Marwell; Waseem Chaudhary; John A Savino; Eric L Alter; Milena J Henzlova; W Lane Duvall
Journal:  J Nucl Cardiol       Date:  2016-02-22       Impact factor: 5.952

7.  Pharmacologic stress myocardial perfusion imaging in patients with pulmonary hypertension: What do we know, and what remains to be learned?

Authors:  Andrew Van Tosh; Kenneth J Nichols
Journal:  J Nucl Cardiol       Date:  2018-06       Impact factor: 5.952

8.  Effect of aminophylline administration on the diagnostic yield of vasodilator myocardial perfusion imaging.

Authors:  Hussein Abu Daya; Fadi G Hage
Journal:  J Nucl Cardiol       Date:  2016-06-03       Impact factor: 5.952

9.  ASNC imaging guidelines for SPECT nuclear cardiology procedures: Stress, protocols, and tracers.

Authors:  Milena J Henzlova; W Lane Duvall; Andrew J Einstein; Mark I Travin; Hein J Verberne
Journal:  J Nucl Cardiol       Date:  2016-06       Impact factor: 5.952

10.  Optimizing patient centered care in the cardiac intensive care unit: Harness the safety, effectiveness, and incremental value of radionuclide perfusion, function, and molecular imaging.

Authors:  Peter A Bleszynski; Ronald G Schwartz
Journal:  J Nucl Cardiol       Date:  2021-06-24       Impact factor: 5.952
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.